Member Info for MB53

The licence agreement with Point was way before PrelCISION had been proven to work in the clinic. Any new licence deal will be very considerably more expensive for the licensee.

As 13thmonkey stated earlier in the thread, Ophidian no longer on group. And anyway, he never ran it.

The poster on Thursday was extremely positive. The 3996 poster would not have been accepted unless it had significant new data. Very exciting and IND next up!

BV - the FDA may approve AVA6000 for only a couple of STS sub types but that will open the floodgates to off-label prescribing. Can you imagine that Dr Tap would not offer all his other STS patients AVA6000? After all, it is just the same Doxorubicin but more efficacious and with minimal side effects. It would be unethical not to. And the same would apply to other oncologists that use Dox for other conditions. As soon as approved, I think demand will increase extremely rapidly and I hope Avacta will have done all the preparation work for this eventuality.

AVA3996 is so much more than just Velcade which because of its toxicity can not be used on solid tumours. 3996 avoids the systemic side effects of Velcade and seems to be effective on solid tumours. It is potentially effective in any FAP producing tumour. It is also potentially worth much much more than AVA6000.

Thanks JT. Obviously it is the responsibility of the doctor and the patient has to be fully informed and agreeable but I don't think that is going to be an issue - Er, do you want the same drug with or without side effects!? I think that is called a no-brainer!

Once AVA6000 gets fast track approval, the drug will be available commercially. It will then be available for any doctor to prescribe Off-Label. That means that a doctor can prescribe a drug for indications other than that for which the drug has been approved (in this case presumably STS). As AVA6000 is basically targeted (more effective) Doxorubicin with much reduced side effects, I would expect Oncologists to start using AVA6000 off-label for any cancer treatments where Doxorubicin is currently used (ie Breast, Ovarian, Lung, Bladder etc). If I were a patient, I would demand it! I suspect the demand for AVA6000 will grow extremely rapidly and I hope that Avacta will have negotiated the manufacturing capability to cope with this demand.

Has anyone got any ideas what AVA6000 will be called when it comes onto the market? Maybe ProDox or precisiondox? Suggestions please!

I think that the problem that Avacta has is that their results so far are "Too good to be true"! And we all know what people say when they hear that - Well, it probably isn't. BP have spent 100s of millions of pounds developing Antibody Drug Conjugates (ADC) which are very expensive, have side effects but do have some increased efficacy. Along comes this little Biotech from Yorkshire with a cheaper targeting solution, better safety profile and potentially much better clinical efficacy. That puts BP in a difficult position - do they abandon ADCs, get a piece of the pre|CISION platform action through licensing/partnerships/TO or do they ignore it and hope that it fails? Hopefully we will find out in the next few months. The market also thinks it is too good to be true and this is reflected in the SP. Once the first licensing/partnership deal hits the market, they will realise that this is something to be taken seriously and I think that the SP will begin to reflect the true value of Avacta more accurately.

I absolutely agree JT - and this gives big Pharma a major headache. Having invested zillions in ADCs they are now faced with a decision on whether to change direction and buy into prelCISION which is clearly a better system for the reasons you stated.

One point that was repeated a number of times at the AGM was that we are “Entering the commercialisation phase of the Platform”. That sounds to me as if they are in discussions or have had significant interest from potential partners/licensees.

Thank you to all those who attended the AGM yesterday and have reported back so comprehensively. One point that was repeated a number of times was that we are “Entering the commercialisation phase of the Platform”. That sounds to me as if they are in discussions or have had significant interest from potential partners/licensees.

Watch this space!

AV -I am in exactly the same investment situation as you and it has been and is stressful. However, having attended yesterday I am more convinced than ever that this company has enormous potential and the ability to change the lives of countless cancer sufferers. We just need patience!

The only news we need now…is confirmation of a licensing deal which will make the company profitable overnight, fund the in house development of AVA6000 and 3996 and prove to the market that Big Pharma acknowledges that Avacta have got something truly amazing in the fight against cancer.

We know that there is a list of the potential generic chemotherapeutic drugs that could be delivered by the Pre|CISION platform. We also know that Avacta may be looking to licence the development of some of these drugs whilst keeping AVA6000 and 3996 in house.

Does anyone have any idea which drug may be the next candidate pro-drug? The therapeutic pipeline does not list any other pure Pre|CISION pro-drugs apart from 6000 and 3996.

Any statisticians on the board? How many paired patients are likely to be needed to show the overwhelming advantage of AVA6000? I reckon the 1b trial will be stopped early due to it becoming unethical to treat with straight Dox.

Any statisticians on the board? How many paired patients are likely to be needed to show the overwhelming advantage of AVA6000? I reckon the 1b trial will be stopped early due to it becoming unethical to treat with straight Dox.

Is the collective noun for Avacta Private Investors “Avactarians”.?

So - not today! Definitely tomorrow! Always in May.

The Annual Report and AGM RNS has been issued on last Tuesday of May for last two years. Watch out for mid-morning RNS.